Roche’s Perjeta regimen gets FDA priority review in breast cancer

ZURICH (Reuters) – The U.S. Food and Drug Administration (FDA) has granted priority review for Roche’s Perjeta in combination with Herceptin and chemotherapy for treating HER2-positive early breast cancer after surgery, Roche said on Friday.

This post was syndicated from Reuters: Health News. Click here to read the full text on the original website.

Be the first to comment

Leave a Reply